{"id":"statin-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, preventing dietary and biliary cholesterol absorption. The combination provides complementary mechanisms to achieve greater LDL-C reduction than either agent alone.","oneSentence":"Statin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:09.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Cardiovascular disease prevention in patients requiring additional LDL-C lowering"}]},"trialDetails":[{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT07447648","phase":"","title":"Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","startDate":"2026-03","conditions":"Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography","enrollment":52},{"nctId":"NCT07445542","phase":"","title":"Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2021-12-18","conditions":"Hypercholesterolemia","enrollment":6927},{"nctId":"NCT07440381","phase":"PHASE3","title":"triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","status":"NOT_YET_RECRUITING","sponsor":"Heart Care Foundation","startDate":"2026-09","conditions":"Acute Coronary Syndromes, Secondary Prevention, Lipids","enrollment":600},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT06740552","phase":"","title":"Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-01-01","conditions":"Multivessel Coronary Artery Disease, Acute Myocardial Infarction (AMI)","enrollment":1862},{"nctId":"NCT07208006","phase":"NA","title":"Very Early PCSK9 Inhibition for Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-01","conditions":"Acute Myocardial Infarction (AMI)","enrollment":1518},{"nctId":"NCT05782777","phase":"NA","title":"Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-04-07","conditions":"Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation","enrollment":4310},{"nctId":"NCT05088759","phase":"NA","title":"Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-10-08","conditions":"Hyperlipemia, Mixed, ASCVD","enrollment":400},{"nctId":"NCT06431763","phase":"PHASE4","title":"A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-06-21","conditions":"Hypercholesterolemia","enrollment":402},{"nctId":"NCT07341958","phase":"NA","title":"INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-02-01","conditions":"Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)","enrollment":242},{"nctId":"NCT05579626","phase":"PHASE4","title":"Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)","status":"ENROLLING_BY_INVITATION","sponsor":"Seung-Whan Lee, M.D., Ph.D.","startDate":"2023-03-14","conditions":"Pre Diabetes, ASCVD","enrollment":4000},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT07255820","phase":"PHASE4","title":"Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol","enrollment":126},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT05910476","phase":"PHASE4","title":"Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-05-03","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":200},{"nctId":"NCT04755413","phase":"NA","title":"The Precision CAD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Coronary Artery Disease","enrollment":276},{"nctId":"NCT04626973","phase":"NA","title":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2021-01-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":3048},{"nctId":"NCT06005597","phase":"PHASE3","title":"Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-03-01","conditions":"Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":407},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT05614765","phase":"","title":"Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-07-08","conditions":"Dyslipidemias","enrollment":18000},{"nctId":"NCT06722521","phase":"PHASE4","title":"GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-09","conditions":"Primary Prevention, Vascular Calcification","enrollment":7435},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT07084259","phase":"PHASE4","title":"Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Hanyang University Seoul Hospital","startDate":"2025-07","conditions":"Coronary Artery Disease","enrollment":352},{"nctId":"NCT06647238","phase":"NA","title":"Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2024-11-05","conditions":"Hyperlipidemia, Coronary Artery Disease","enrollment":80},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT07036991","phase":"PHASE4","title":"Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-30","conditions":"Carotid Artery Stenosis","enrollment":406},{"nctId":"NCT06649240","phase":"NA","title":"Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-10-04","conditions":"Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL","enrollment":4016},{"nctId":"NCT03110432","phase":"","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2017-05-18","conditions":"Dyslipoproteinemias, Hypercholesterolemia, Familial, Familial Hypercholesterolemia - Homozygous","enrollment":1695},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":"ASCVD, Diabetes, Statin","enrollment":2000},{"nctId":"NCT05368545","phase":"NA","title":"Influence of Lipid Lowering on Impaired Coronary Flow","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2020-05-15","conditions":"Coronary Artery Disease","enrollment":109},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":"Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder","enrollment":200},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT05255094","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-11-03","conditions":"Hyperlipidemia","enrollment":464},{"nctId":"NCT05260411","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-01-26","conditions":"Hyperlipidemia","enrollment":246},{"nctId":"NCT06854523","phase":"NA","title":"Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)","status":"NOT_YET_RECRUITING","sponsor":"Yun Dai Chen","startDate":"2025-04-15","conditions":"Acute Myocardial Infarction","enrollment":300},{"nctId":"NCT05255458","phase":"PHASE3","title":"A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-11-04","conditions":"Hyperlipidemia","enrollment":122},{"nctId":"NCT06821711","phase":"NA","title":"Optimal LDL-C Target in High-risk Patients After PCI","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-02-20","conditions":"Chronic Coronary Syndrome, Acute Coronary Syndromes, Percutaneous Coronary Intervention","enrollment":12000},{"nctId":"NCT06784557","phase":"PHASE4","title":"Effect of Ezetimibe on Gut Microbiota","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-02-28","conditions":"Atherosclerotic Cardiovascular Disease With Dyslipidemia","enrollment":110},{"nctId":"NCT05845424","phase":"PHASE4","title":"High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2023-07-03","conditions":"Coronary Artery Calcification, Metabolic Syndrome, Dyslipidemias","enrollment":6000},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT04303377","phase":"PHASE2","title":"Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction","status":"WITHDRAWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-11-18","conditions":"ST-elevation Myocardial Infarction","enrollment":""},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT04807400","phase":"PHASE3","title":"Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-07","conditions":"Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol","enrollment":892},{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT06293417","phase":"NA","title":"To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-03-01","conditions":"T2DM (Type 2 Diabetes Mellitus), Dyslipidemias","enrollment":3958},{"nctId":"NCT06567418","phase":"","title":"Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-08-01","conditions":"Acute Coronary Syndrome","enrollment":10000},{"nctId":"NCT04701242","phase":"NA","title":"Ezetimibe Utilization Early After Acute Myocardial Infarction, \"EzAMI Trial\"","status":"RECRUITING","sponsor":"Cairo University","startDate":"2021-03-24","conditions":"Acute Myocardial Infarction, Dyslipidemias","enrollment":500},{"nctId":"NCT00651963","phase":"PHASE4","title":"Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-09","conditions":"Lipid Metabolism Disorder","enrollment":80},{"nctId":"NCT00092586","phase":"PHASE3","title":"Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":2904},{"nctId":"NCT00652847","phase":"PHASE4","title":"Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia","enrollment":1140},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00395603","phase":"PHASE3","title":"Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Cardiovascular Diseases, Diabetes Mellitus","enrollment":550},{"nctId":"NCT00328523","phase":"PHASE3","title":"TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06","conditions":"Hypercholesterolaemia, Hyperlipidaemia","enrollment":1496},{"nctId":"NCT05266586","phase":"PHASE2","title":"Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2022-03-09","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":119},{"nctId":"NCT00653523","phase":"PHASE3","title":"Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":151},{"nctId":"NCT00654095","phase":"PHASE3","title":"Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":146},{"nctId":"NCT00479713","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-01","conditions":"Hypercholesterolemia","enrollment":618},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT00395473","phase":"PHASE3","title":"Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-03","conditions":"Hypercholesterolemia","enrollment":141},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT05974345","phase":"","title":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":204691},{"nctId":"NCT04770389","phase":"PHASE2","title":"Randomized Study of Obicetrapib in Combination With Ezetimibe","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2021-02-23","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":112},{"nctId":"NCT06381947","phase":"PHASE4","title":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Salerno","startDate":"2024-05-01","conditions":"Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT05361421","phase":"PHASE4","title":"Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-07-19","conditions":"Cardiovascular Disease","enrollment":1200},{"nctId":"NCT05587621","phase":"NA","title":"Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)","status":"NOT_YET_RECRUITING","sponsor":"Jena University Hospital","startDate":"2024-04-01","conditions":"ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol","enrollment":300},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT04719221","phase":"PHASE4","title":"Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2021-03-01","conditions":"Clinical Trial, Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT01308203","phase":"PHASE4","title":"Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Daniel A. Siniawski","startDate":"2011-10","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":32},{"nctId":"NCT04826354","phase":"PHASE4","title":"Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2021-08-11","conditions":"Atheroscleroses, Coronary","enrollment":582},{"nctId":"NCT05765370","phase":"NA","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-03-24","conditions":"Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol","enrollment":4200},{"nctId":"NCT03933293","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-05-13","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT04173403","phase":"PHASE2","title":"A Long-term Study of AK102 in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-11-04","conditions":"Hypercholesterolemia","enrollment":796},{"nctId":"NCT04173793","phase":"PHASE2","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-11-18","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":109},{"nctId":"NCT04358432","phase":"PHASE2","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2020-05-13","conditions":"Hypercholesterolemia","enrollment":262},{"nctId":"NCT02534376","phase":"EARLY_PHASE1","title":"Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":63},{"nctId":"NCT04895098","phase":"","title":"Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD","status":"COMPLETED","sponsor":"Akrikhin","startDate":"2021-06-23","conditions":"Lipid Metabolism Disorders, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT05546398","phase":"","title":"SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2022-04-22","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":500},{"nctId":"NCT05613400","phase":"PHASE4","title":"Statin and Bone Health","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-13","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT01587235","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-03","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00726856","phase":"","title":"Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Dyslipidemia","enrollment":1200},{"nctId":"NCT01236430","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-02","conditions":"Hyperlipidemia","enrollment":200},{"nctId":"NCT00704535","phase":"","title":"Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia","enrollment":4105},{"nctId":"NCT00705081","phase":"","title":"Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-01","conditions":"Hypercholesterolemia","enrollment":453},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD TRIGLYCERIDES INCREASED"},{"count":1,"reaction":"HYPERGLYCAEMIA"}],"_approvalHistory":[],"publicationCount":237,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anticholesterol drug"],"phase":"marketed","status":"active","brandName":"statin + ezetimibe","genericName":"statin + ezetimibe","companyName":"University of Roma La Sapienza","companyId":"university-of-roma-la-sapienza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Statin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular disease prevention in patients requiring additional LDL-C lowering.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}